ID
32557
Beskrivning
Study ID: 106837 Clinical Study ID: HZA106837 Study Title: A Long-Term, Randomized, Double-Blind, Parallel Group Study of Fluticasone Furoate/GW642444 Inhalation Powder Once-Daily and Fluticasone Furoate Inhalation Powder Once-Daily in Subjects with Asthma Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01086384 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: fluticasone furoate/vilanterol Trade Name: Relvar Study Indication: Asthma
Nyckelord
Versioner (2)
- 2018-11-06 2018-11-06 -
- 2018-12-06 2018-12-06 -
Rättsinnehavare
GSK group of companies
Uppladdad den
6 november 2018
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
A Parallel Group Study of Fluticasone Furoate/Vilanterol in Subjects with Asthma - 106837
Study conclusion
- StudyEvent: ODM
Beskrivning
If YES, complete primary reason for withdrawal
Beskrivning
record details on AE or SAE forms as appropriate)
Datatyp
boolean
Beskrivning
Check all that apply. If none, select "No Subreasons"
Datatyp
text
Beskrivning
Check all that apply. If none, select "No Subreasons"
Datatyp
text
Beskrivning
4. Subject reached protocol defined stopping criteria
Datatyp
text
Beskrivning
5. Study closed/terminated
Datatyp
boolean
Beskrivning
6. Lost to Follow-Up
Datatyp
boolean
Beskrivning
Select this reason if none of the other primary reasons are appropriate
Datatyp
text
Beskrivning
Select this reason if none of the other primary reasons are appropriate
Datatyp
text
Similar models
Study conclusion
- StudyEvent: ODM